Sucampo Pharmaceuticals / SCMP
About Sucampo Pharmaceuticals
4520 East West Hwy., Third Floor, Bethesda, Md. 20814
www.sucampo.com
| 301-961-3400
| Founded: 1996
Industry: Biotechnology | Category: Public Companies
Sucampo Pharmaceuticals focuses on the development and commercialization of drugs derived from human fatty acids called prostones. The company went public in August, raising an estimated $28.4 million in its initial public offering. It markets a drug called Amitiza, a treatment for chronic constipation. The company says it plans to use its IPO proceeds to market Amitiza and develop other drugs, including treatments for ulcers and diseases that affect blood vessels and the central nervous system.
2007 Financial Data
Revenues: $91,891,000 | Net Income: $13,190,000Asssets: $110,027,000 | Earnings Per Share: $0.35
Stockholder Equity: $86,528,000 | Annual Dividend: $0.00
Total employees: 104 | Local employees: 53
Company Leadership
| Anthony C. Celeste | Director |
| Michael J. Jeffries | Director |
| Timothy I. Maudlin | Director |
| Hidetoshi Mine | Director |
| V. Sue Molina | Director |
| Ryuji Ueno | Co-Founder, Chairman, Chief Executive Officer and Chief Scientific Officer |
| John C. Wright | Independent Director |
| Ryuji Ueno | Chairman, Chief Scientific Officer and Chief Executive Officer |
Source: Compensation data provided by Equilar, Inc..
| Ryuji Ueno Chairman, Chief Scientific Officer and Chief Executive Officer | $6,680,778 Salary: $478,846 |
Did You Know
CLEAR VISION: Sucampo was founded in 1996 by Japanese biochemists Ryuji Ueno and Sachiko Kuno after they successfully developed Rescula Eye Drops, an anti-glaucoma drug.
